Showing 2481-2490 of 2530 results for "".
- Complications After Intravitreal Injection Aggravatehttps://modernod.com/news/complications-after-intravitreal-injection-aggravate/2480023/Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and best practices at the upcoming American Society of Retina Specialists (ASRS) 2018 Annual Meeting, according to a
- Iridex Reaches Milestone of 1000th Cyclo G6 System Shippedhttps://modernod.com/news/iridex-reaches-milestone-of-1000th-cyclo-g6-system-shipped/2480033/Iridex announced that in the second quarter of 2018 it shipped the 1,000th unit of its »Cyclo G6 Laser System, which utilizes the company’s propri
- Takeda Receives Clearance from the FTC for the Proposed Acquisition of Shirehttps://modernod.com/news/takeda-receives-clearance-from-the-ftc-for-the-proposed-acquisition-of-shire/2480035/Takeda Pharmaceutical announced that it has received unconditional clearance from the United States Federal Trade Commission (FTC) for the proposed acquisition of Shire announced on May 8, 2018. Takeda’s proposed acquisition of Shire is valued at around 46 billion pounds ($60.9 billion).
- Eyenovia Appoints Michael Rowe as Vice President of Marketinghttps://modernod.com/news/eyenovia-appoints-michael-rowe-as-vice-president-of-marketing/2480038/Eyenovia announced the appointment of Michael Rowe as Vice President of Marketing. Mr. Rowe is a veteran marketing professional with more than 20 years of experience in commercializing products and devices in the United States and globally across the healthcare industry.
- Sue Anschutz-Rodgers Eye Center: A Highly Visible Legacy of Longstanding Philanthropic Partnershiphttps://modernod.com/news/sue-anschutz-rodgers-eye-center-a-highly-visible-legacy-of-longstanding-philanthropic-partnership/2480040/The University of Colorado Anschutz Medical Campus and UCHealth announced the naming of the UCHealth Eye Center program for philanthropist Sue Anschutz-Rodgers, who has made leadership gifts to accelerate innovative r
- Study: Combined Cataract Surgery Ups Postop Endophthalmitis Riskhttps://modernod.com/news/study-combined-cataract-surgery-ups-postop-endophthalmitis-risk/2480042/Patients who undergo combined cataract surgery, or removal of cataracts combined with treatment of other eye disorders during the same procedure, have higher incidence of acute postoperative endophthalmitis (acute POE) compared with those who have cataract surgery alone, results of a French natio
- Lin BioScience Receives EMA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Diseasehttps://modernod.com/news/lin-bioscience-receives-ema-orphan-drug-status-for-lbs-008-for-the-treatment-of-stargardt-disease/2480056/Lin BioScience announced that the European Medicines Agency has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. Stargardt Disease is currently an untreatable inherited condition that causes permanent vision loss in children
- Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45 Million Public Offering of Common Stockhttps://modernod.com/news/aerpio-pharmaceuticals-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-45-million-public-offering-of-common-stock/2480066/Aerpio Pharmaceuticals announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018, following its previously announced approval to list its common stock on the Nasdaq Capital Market. Aerpio also announce
- EyePoint Pharmaceuticals Announces Stockholder Approval of Second Tranche of Capital Financinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-stockholder-approval-of-second-tranche-of-capital-financing/2480070/EyePoint Pharmaceuticals announced that it has received stockholder approval for the second tranche of growth capital under a Securities Purchase Agreement (Second Tranche Transaction) with Essex Woodland (EW) Healthcare Partners, a healthcare-focused investment firm; Rosalind Advisors; and anoth
- Bio-Tissue Highlights Publication of DREAM Studyhttps://modernod.com/news/bio-tissue-highlights-publication-of-dream-study/2480079/Bio-Tissue highlighted the publication of the Dry Eye Amniotic Membrane (DREAM) study in Clinical Ophthalmology.[1] This retrospective study was conducted at 10 clinical sites in the United States, led by Marguerite McDonald, MD, and Hosam Sheha, MD. It demonstrates that a single applica